[go: up one dir, main page]

DZ2742A1 - Nouveaux procédés pour la préparation de (r)-beta-(2,3-diméthoxy phényl)-1-Ä2-(4-fluorophényl)éthylÜ-4-pipéridineméthanol. - Google Patents

Nouveaux procédés pour la préparation de (r)-beta-(2,3-diméthoxy phényl)-1-Ä2-(4-fluorophényl)éthylÜ-4-pipéridineméthanol.

Info

Publication number
DZ2742A1
DZ2742A1 DZ990043A DZ990043A DZ2742A1 DZ 2742 A1 DZ2742 A1 DZ 2742A1 DZ 990043 A DZ990043 A DZ 990043A DZ 990043 A DZ990043 A DZ 990043A DZ 2742 A1 DZ2742 A1 DZ 2742A1
Authority
DZ
Algeria
Prior art keywords
ethylü
piperidinemethanol
fluorophenyl
beta
preparation
Prior art date
Application number
DZ990043A
Other languages
English (en)
French (fr)
Inventor
Alan G Bina
Edward D Daugs
Jonathan C Evans
Hans W Flemming
Gerard Guillamot
Robert A Hawthorne
Thomas H E Hilpert
James E Hitt
Chi-Hsin R King
Johannes N Koek
Frederick M Laskovics
John R Lefler
Alexy L Margolin
Sharon K Minish
Thomas T Ortyl
Lian G Rajewski
Marvin J Sack
Paul F Skultety
Sandra K Stolz-Dunn
Alonzo L Tigner
Ian A Tolinson
Original Assignee
Hoechst Marion Roussel Inc
Hoechst Marion Roussel De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc, Hoechst Marion Roussel De Gmbh filed Critical Hoechst Marion Roussel Inc
Application granted granted Critical
Publication of DZ2742A1 publication Critical patent/DZ2742A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DZ990043A 1998-03-13 1999-03-10 Nouveaux procédés pour la préparation de (r)-beta-(2,3-diméthoxy phényl)-1-Ä2-(4-fluorophényl)éthylÜ-4-pipéridineméthanol. DZ2742A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4225198A 1998-03-13 1998-03-13
US25071899A 1999-02-16 1999-02-16

Publications (1)

Publication Number Publication Date
DZ2742A1 true DZ2742A1 (fr) 2003-09-08

Family

ID=26719032

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990043A DZ2742A1 (fr) 1998-03-13 1999-03-10 Nouveaux procédés pour la préparation de (r)-beta-(2,3-diméthoxy phényl)-1-Ä2-(4-fluorophényl)éthylÜ-4-pipéridineméthanol.

Country Status (25)

Country Link
EP (3) EP1734037A3 (no)
JP (2) JP4511723B2 (no)
KR (7) KR100591640B1 (no)
CN (1) CN100436415C (no)
AR (1) AR015540A1 (no)
AT (1) ATE373639T1 (no)
AU (1) AU755436B2 (no)
BR (1) BR9909260A (no)
CA (1) CA2322501C (no)
CY (1) CY1107104T1 (no)
DE (1) DE69937162T2 (no)
DK (1) DK1192134T3 (no)
DZ (1) DZ2742A1 (no)
EG (1) EG24052A (no)
ES (1) ES2294838T3 (no)
HK (1) HK1042484B (no)
HU (1) HUP0400889A3 (no)
IL (3) IL138307A0 (no)
MA (1) MA25515A1 (no)
NO (1) NO317981B1 (no)
NZ (1) NZ506807A (no)
PT (1) PT1192134E (no)
TN (1) TNSN99035A1 (no)
TW (1) TWI249526B (no)
WO (1) WO1999046245A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713627B2 (en) * 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
DE19934432A1 (de) 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
WO2002072069A1 (en) * 2001-03-12 2002-09-19 Novo Nordisk A/S Novel tablets and capsules and a process for its preparation
DE102004010132A1 (de) 2004-02-27 2005-09-15 Merck Patent Gmbh Piperidinderivate
TWI428151B (zh) * 2006-12-07 2014-03-01 Daiichi Sankyo Co Ltd 含有甘露醇或乳糖之固形製劑
US8964338B2 (en) 2012-01-11 2015-02-24 Emerson Climate Technologies, Inc. System and method for compressor motor protection
WO2014144446A1 (en) 2013-03-15 2014-09-18 Emerson Electric Co. Hvac system remote monitoring and diagnosis
CN112358398A (zh) * 2020-11-19 2021-02-12 山东新华制药股份有限公司 D-(+)-二对甲苯甲酰酒石酸的回收制备方法
CN116082705B (zh) * 2022-12-05 2023-09-12 苏州易昇光学材料股份有限公司 一种抗黄变自修复凝胶

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260623A (en) * 1979-11-26 1981-04-07 Warner-Lambert Company Hexahydro-1-arylspiro(3H-oxazolo(3,4-A)pyridine-3,4'-piperidene) antidepressants, pharmaceutical compositions thereof and method of use thereof
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
CA1280421C (en) * 1985-07-02 1991-02-19 Albert A. Carr 1,4-disubstituted piperidinyl derivatives
HU213271B (en) * 1990-06-01 1997-04-28 Merrell Dow Pharma Process for producing (+)-alpha-(2,3-dimethoxi-phenyl)-1-[2-(4-fluoric-phenyl)-ethyl]-4-piperidine-methanole and pharmaceutical compositions containing the same
ATE144899T1 (de) * 1990-06-07 1996-11-15 Merrell Pharma Inc Derivate des 1-piperidinyl- alkanoylarylsulfonamids
US5477029A (en) * 1994-01-28 1995-12-19 Skutt Ceramic Products, Inc. Kiln with hinged control panel
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Also Published As

Publication number Publication date
KR20060002034A (ko) 2006-01-06
KR100591640B1 (ko) 2006-06-20
IL175983A0 (en) 2006-10-05
CN100436415C (zh) 2008-11-26
KR100591642B1 (ko) 2006-06-20
KR100591641B1 (ko) 2006-06-20
CA2322501A1 (en) 1999-09-16
EP1734037A3 (en) 2010-06-16
NO317981B1 (no) 2005-01-17
KR20060002038A (ko) 2006-01-06
CN1300280A (zh) 2001-06-20
HUP0400889A2 (hu) 2004-08-30
DE69937162T2 (de) 2008-06-12
NO20004545D0 (no) 2000-09-12
NO20004545L (no) 2000-11-13
EP1192134A2 (en) 2002-04-03
KR100586327B1 (ko) 2006-06-08
KR20060002039A (ko) 2006-01-06
KR100591643B1 (ko) 2006-06-20
EP1736469A2 (en) 2006-12-27
JP2010143925A (ja) 2010-07-01
WO1999046245A3 (en) 1999-10-21
PT1192134E (pt) 2007-11-13
HK1042484A1 (en) 2002-08-16
TNSN99035A1 (fr) 2005-11-10
EP1192134B1 (en) 2007-09-19
JP2002506059A (ja) 2002-02-26
KR20010041819A (ko) 2001-05-25
MA25515A1 (fr) 2002-10-01
AR015540A1 (es) 2001-05-02
AU755436B2 (en) 2002-12-12
IL138307A0 (en) 2001-10-31
EP1736469A3 (en) 2010-06-09
HK1042484B (zh) 2008-05-02
DK1192134T3 (da) 2007-11-26
CY1107104T1 (el) 2012-01-25
HUP0400889A3 (en) 2010-08-30
ES2294838T3 (es) 2008-04-01
BR9909260A (pt) 2000-11-21
ATE373639T1 (de) 2007-10-15
WO1999046245A2 (en) 1999-09-16
CA2322501C (en) 2006-05-09
KR100586328B1 (ko) 2006-06-08
NZ506807A (en) 2003-03-28
DE69937162D1 (de) 2007-10-31
EP1734037A2 (en) 2006-12-20
TWI249526B (en) 2006-02-21
KR20060002037A (ko) 2006-01-06
KR100591997B1 (ko) 2006-06-26
AU2998899A (en) 1999-09-27
KR20060002035A (ko) 2006-01-06
EG24052A (en) 2008-04-13
KR20060002036A (ko) 2006-01-06
JP4511723B2 (ja) 2010-07-28
IL138307A (en) 2006-09-05

Similar Documents

Publication Publication Date Title
DZ2247A1 (fr) Procédé pour la préparation du sildénafil.
DZ3079A1 (fr) Procédé pour la préparation de 4-carboxy-amino-2-substitué-1,2,3,4 tétrahydroquinolé.
NO20011214D0 (no) FremgangsmÕte for fremstilling av aromatiske aldehyder
HK1031869A1 (en) 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds.
NO20011936L (no) Fremgangsmate for fremstilling av citalopram
HK1043130A1 (en) Method for the preparation of 5-cyanophthalide.
ITBO970640A0 (it) Apparecchio per l'elettroemanazione di principi attivi.
DZ2912A1 (fr) Procédé pour la préparation de pyrazolo Ä4,3-DÜpyrimidine-7-ones, et intermédiaires pour ce procédé.
DZ2641A1 (fr) Nouveaux procédés pour la préparation d'oméprazole.
DZ2742A1 (fr) Nouveaux procédés pour la préparation de (r)-beta-(2,3-diméthoxy phényl)-1-Ä2-(4-fluorophényl)éthylÜ-4-pipéridineméthanol.
GB2343892B (en) Process for the preparation of d,l-menthol
NO985535D0 (no) FremgangsmÕte for fremstilling av 1,3-alkandioler
TR199700174A2 (tr) Asimetrik 4,6-bis(ariloksi)pirimidin bilesiklerinin hazirlanmasi icin proses.
DE69913635D1 (de) Verfahren zur Herstellung von 1,3-Dialkyl-2-Imidazolinonderivaten
DZ2770A1 (fr) Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
MA24464A1 (fr) Procede de preparation de composes nouveaux .
ZA200102818B (en) Process for the preparation of 4,4'-dihalogen-O-hydroxydiphenyl compounds.
FI964829A0 (fi) Menetelmä 2,2,4-trimetyyli-1,3-pentaanidioli-isobutyraatin valmistamiseksi
NO20005158D0 (no) FremgangsmÕte for fremstilling av R-(+)-6-karboksamido-3-N- metylamino-1,2,3,4-tetrahydrokarbazol
PT1133495E (pt) Semi-hidrocloreto do acido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diazabiciclo-¬4.3.0|-nonano-8-il)-6-fluoro-1,4-diidro-4-oxo-3-quinolinocarboxilico
FR2778917B1 (fr) Nouveaux derives d'histidine, procede de preparation et utilisations
NO20005743L (no) Fremgangsmåte til fremstilling av 4,5-epoksymorfinan-6- glukuronider
ZA991215B (en) Process for the preparation of 1,3-disubstituted 2-nitroguanidines.
NO932920L (no) Forbedret fremgangsmaate for fremstilling av ikke-ioniske,overflateaktive forbindelser
DE59904904D1 (de) Verfahren zur Herstellung von Phenyldichloro-1,3,5-triazinverbindungen